Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline

Area of Science:

• Cardiovascular Medicine
• Clinical Trials
• Pharmacovigilance

Background:

• Real-world statin side effect data may be biased due to non-randomized and unblinded use.
• Innovative study designs can mitigate biases in assessing drug safety.
• Previous trials suggest patient-reported events differ between blinded and unblinded settings.

Purpose of the Study:

• To evaluate serious adverse events (SAEs) associated with statin use at baseline.
• To analyze SAEs within the context of the SPRINT blood pressure management trial.

Main Methods:

• Serious adverse event (SAE) rates were computed based on statin use at baseline.
• Analyses included overall and treatment-related SAEs.
• Adjusted hazard ratios for statin use were calculated across four defined cohorts.

Main Results:

• Statin use was not linked to increased overall or treatment-related SAEs in participants without pre-existing cardiovascular disease (CVD).
• No increased SAE rates were observed in those randomized to standard blood pressure management, irrespective of CVD status.
• A modest but significant rise in overall SAEs was noted among high-risk patients with existing CVD receiving intensive blood pressure management and statin therapy.

Conclusions:

• Statin use in the SPRINT trial was generally not associated with a higher risk of SAEs.
• An increased risk of overall SAEs was observed specifically in higher-risk patients using statins.
• Potential confounding factors include pre-existing CVD and polytherapy in intensive blood pressure management.